IP Library Granted Patent US 7,799,907
Granted Patent B2
US 7,799,907 · App. 11/573,869 · Granted Sep 21, 2010

Method for the preparation of 2′-deoxy-2′,2′-difluorocytidine

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,799,907
App. No.
11/573,869
Granted
Sep 21, 2010
Kind
B2
Abstract

Provided is an improved method for stereoselectively preparing 2′-deoxy-2′,2′-difluorocytidine of formula (I), which includes reacting a 1-halo ribofuranose compound with a nucleobase of formula (IV) in a solvent to obtain a nucleo side of formula (II) with removal of a silyl halide ((alkyl) 3 SiX (X=halide)); and deprotecting the nucleoside of formula (II) to obtain 2′-deoxy-2′,2′-difluorocytidine of formula (I). 2′-Deoxy-2′,2′-difluorocytidine of formula (I) is effective for treating various cancers such as non-small cell lung (NSCLC), pancreatic, bladder, breast or ovarian cancers.

Claims (28)

1. A method for preparing 2′-deoxy-2′,2′-difluorocytidine of formula (I), which comprises the steps of

(i) reacting a 1-halo ribofuranose compound of formula (III) with a nucleobase of formula (IV) in a solvent to obtain a nucleoside of formula (II) while continuously removing a silyl halide of formula (V) produced during the reaction; and

(ii) deprotecting the nucleoside of formula (II) by reacting the nucleoside of formula (II) with at least one selected from the group consisting of water, an alcohol, a base, an acid catalyst, and an acidic ion exchange resin to obtain 2′-deoxy-2′,2′-difluorocytidine of formula (I):

wherein,

R is an alkyl;

P 1 is a hydroxy-protecting group;

P 2 is an amino-protecting group; and

X is a halogen.

2. The method of claim 1 , wherein the removal of the silyl halide in step i) is carried out by distillation.

3. The method of claim 1 , wherein the nucleobase of formula (IV) present in step i) is in an amount ranging from 5 to 50 molar equivalents based on 1 molar equivalent of 1-halo ribofuranose of formula (III).

4. The method of claim 1 , wherein the solvent present in step i) is selected from the group consisting of benzene, substituted benzene, toluene, xylene, decalin, diglyme, 2-ethoxyethyl ether, diphenylether, substituted diphenylether, biphenyl, substituted biphenyl, C 6-14 alkane, substituted C 6-14 alkane and a mixture thereof.

5. The method of claim 1 , wherein the silyl halide of formula (V) is trimethylsilylbromide.

6. The method of claim 2 , further comprising adding a volatile solvent carrier to a reaction mixture, when the distillation is carried out.

7. The method of claim 6 , wherein the carrier is selected from the group consisting of benzene, substituted benzene, toluene, xylene, C 6-14 alkane, substituted C 6-14 alkane and a mixture thereof.

8. The method of claim 7 , wherein the carrier is heptane.

9. The method of claim 6 , wherein the carrier is present in an amount ranging from 50 to 1000 ml based on 1 g of 1-halo ribofuranose.

10. The method of claim 6 , further comprising adding a heating medium or N,O-bis(trimethylsilyl)acetamide (BSA) to the reaction mixture, when adding the volatile solvent carrier to the reaction mixture.

11. The method of claim 10 , wherein the heating medium is selected from the group consisting of decalin, diphenylether, substituted diphenylether, biphenyl, substituted biphenyl and a mixture thereof.

12. The method of claim 11 , wherein the heating medium is diphenylether.

13. The method of claim 10 , wherein the heating medium is present in an amount ranging from 0.1 to 5 vol % based on the amount of the carrier.

14. The method of claim 10 , wherein N,O-bis(trimethylsilyl)acetamide (BSA) is present in an amount ranging from 0.05 to 1.5 vol % based on the amount of the carrier.

15. The method of claim 1 , wherein the removal of the silyl halide in step i) is carried out by passing an inert gas through the reaction mixture.

16. The method of claim 15 , wherein the inert gas is selected from the group consisting of nitrogen, helium, neon and argon.

17. The method of claim 15 , wherein the inert gas is introduced in the form of bubbling or sweeping.

18. The method of claim 15 , wherein the inert gas is introduced at a flow rate of 1 l/min or more based on 100 g of 1-halo ribofuranose of formula (III).

19. The method of claim 1 , wherein step i) is carried out at a temperature ranging from 80 to 300° C.

20. The method of claim 1 , which in step ii), further comprising after the deprotection, the steps of dissolving the nucleoside of formula (II) in the form of an α/β anomer mixture in water; heating the resulting solution to a temperature of 40 to 60° C.; cooling the solution to a temperature ranging from 10 to 25° C. with or without stirring and without pH-adjustment; and filtering precipitated solids to obtain 2′-deoxy-2′,2′-difluorocytidine of formula (I).

21. The method of claim 1 further comprising preparing the hydrochloride salt of 2′-deoxy-2′,2′-difluorocytidine of formula (I) by reacting 2′-deoxy-2′,2′-difluorocytidine of formula (I) or a hemihydrate or dihydrate thereof with hydrochloric acid in an organic solvent.

Assignments (3)
CHANGE OF NAME Recorded Aug 3, 2012
From: HANMI HOLDINGS CO., LTD.
To: HANMI SCIENCE CO., LTD.
Reel/Frame 028722/0332 →
CHANGE OF NAME Recorded Jan 7, 2011
From: HANMI PHARM. CO., LTD.
To: HANMI HOLDINGS CO., LTD.
Reel/Frame 025599/0984 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2007
From: LEE, JAEHEON; PARK, GHA SEUNG; LEE, MOONSUB; BANG, HYO-JEONG; LEE, JAE CHUL; KIM, CHEOL KYONG; CHOI, CHANG-JU; KIM, HAN KYONG; LEE, HOE CHUL; CHANG, YOUNG-KIL; LEE, GWAN SUN
To: HANMI PHARM. CO., LTD.
Reel/Frame 018920/0913 →